Neurogene (NGNE) Operating Leases (2019 - 2026)

Neurogene has reported Operating Leases for 8 years, with the latest figure at $6.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 29.36% year-over-year to $6.1 million; the trailing twelve-month figure through Mar 2026 stood at $6.1 million (down 29.36% YoY), and the FY2025 full-year result was $6.8 million, down 44.75% from the prior year.
• Operating Leases for Q1 2026 stood at $6.1 million, down from $6.8 million in the prior quarter.
• The five-year high for Operating Leases was $14.9 million in Q4 2023, with the low at $4.6 million in Q4 2022.
• Historically, Operating Leases has averaged $9.6 million across 5 years, with a median of $9.9 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Leases soared 359.9% — and 2025, when it tumbled 44.75%.
• Neurogene's Operating Leases stood at $4.6 million in 2022, then soared by 223.14% to $14.9 million in 2023, then retreated by 16.91% to $12.3 million in 2024, then plunged by 44.75% to $6.8 million in 2025, then decreased by 10.89% to $6.1 million in 2026.
• The last three Operating Leases figures came in at $6.1 million (Q1 2026), $6.8 million (Q4 2025), and $7.1 million (Q3 2025), per Business Quant data.